Fig. 5From: Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthmaAdjusted mean FVC AUC0–24 at 3 weeks. FVC: forced vital capacity; AUC0–24: area under the curve from 0 to 24 h; SE: standard error; BID: twice daily; QD: once dailyBack to article page